SCHEMBL676864

SCHEMBL676864

CN(C)C(=Nc1cccc2cccc(N=C(N(C)C)N(C)C)c12)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
SIGMAR1 Q99720 8/20 0.38
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A1 P04798 1/20 0.36
HPGD P15428 1/20 0.36
CYP1B1 Q16678 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR2A P28223 2/20 0.34
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
TP53 P04637 1/20 0.31
THPO P40225 1/20 0.31
MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5746772 0.98 MAPT (0.40) KDM4EGAAMAPTSIGMAR1CYP1A2
SCHEMBL5747124 0.94 CYP3A4 (0.40) KDM4EGAAMAPTSIGMAR1CYP1A2
SCHEMBL5745827 0.92 KDM4E (0.39) KDM4EGAAMAPTSIGMAR1CYP1A2
SCHEMBL13967904 0.86 KDM4E (0.32) KDM4EGAAMAPTSIGMAR1
SCHEMBL16376115 0.86 HTR2A (0.34) KDM4EGAAMAPTSIGMAR1HTR2A
SCHEMBL13967928 0.86 KDM4E (0.32) KDM4EGAAMAPTSIGMAR1
SCHEMBL13967975 0.85 SIGMAR1 (0.45) SIGMAR1CYP1A2CYP3A4ALDH1A1HPGD
SCHEMBL13967926 0.85 KDM4E (0.34) KDM4EGAAMAPTSIGMAR1CYP1A2
SCHEMBL13967982 0.84 KDM4E (0.33) KDM4EGAAMAPTSIGMAR1
SCHEMBL13967970 0.82 SIGMAR1 (0.33) KDM4EGAAMAPTSIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-02 US claimed
CN-114630835-B Process for the preparation of peptide compounds comprising sterically bulky amino acids 中外制药株式会社 2025-02-11 CN claimed
CN-119362542-A Electric automobile group charging method based on cooperative optimization of traffic network and micro-grid 湖南工业大学 2025-01-24 CN claimed
EP-4486459-A1 HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF Yale University (US) 2025-01-08 EP claimed
US-20240421302-A1 OLIVINE COMPOSITE CATHODE MATERIAL, PREPARATION METHOD AND APPLICATION THEREOF, AND LITHIUM-ION BATTERY BEIJING EASPRING MATERIAL TECHNOLOGY CO., LTD. (CN) 2024-12-19 US claimed
EP-4468404-A1 OLIVINE COMPOSITE POSITIVE-ELECTRODE MATERIAL, PREPARATION METHOD AND APPLICATION THEREOF, AND LITHIUM-ION BATTERY Beijing Easpring Material Technology Co., Ltd. (CN) 2024-11-27 EP claimed
WO-2023168352-A1 HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF YALE UNIVERSITY (US) 2023-09-07 WO claimed
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-26 US claimed
CN-115358783-A Multi-electric vehicle and multi-micro-grid multi-party game energy trading system based on reinforcement learning and multiple constraints 湖南工业大学 2022-11-18 CN claimed
EP-4056580-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-14 EP claimed
CN-114630835-A Process for the preparation of peptide compounds comprising sterically bulky amino acids 中外制药株式会社 2022-06-14 CN claimed
EP-4225822-B1 METHOD FOR PRODUCING POLYURETHANE FOAMS OR HYDROGELS BY EMPLOYING DIOL CONTAINING FORMULATIONS COVESTRO DEUTSCHLAND AG (DE) 2026-05-13 EP disclosed
EP-4678652-A1 METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-01-14 EP disclosed
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-02 US disclosed
EP-4570813-A1 METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-18 EP disclosed
US-20090186993-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-23 US disclosed
EP-1990371-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-12 EP disclosed
US-20070173557-A1 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst KETTENBACH GMBH & CO. KG (DE) 2007-07-26 US disclosed
US-20070173557-A1 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst KETTENBACH GMBH & CO. KG (DE) 2007-07-26 US disclosed
EP-1738737-A1 Dimensionally stable articles from cured condensation-crosslinked dental material Kettenbach GmbH & CO. KG (DE) 2007-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173557-A1 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst CSNK1A1L, TBL3, DCLK3 KDM4E 3211/4885GAA 2438/4885MAPT 2308/4885
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID DNPEP, VIP, NPEPPS KDM4E 4275/4885GAA 1224/4885MAPT 2810/4885
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid DNPEP, VIP, NPEPPS KDM4E 4275/4885GAA 1224/4885MAPT 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.